Top

Published in:

01-09-2008 | Preclinical Study

Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast

Authors: Emad A. Rakha, Maysa E. El-Sayed, Sindhu Menon, Andrew R. Green, Andrew H. S. Lee, Ian O. Ellis

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Invasive lobular carcinoma (ILC) comprises approximately 5–15% of breast cancers and appears to have a distinct biology. As it is less common than invasive ductal carcinoma, few studies of large size have addressed the value of assessment of histologic grade in ILC. Methods: This study is based on a large and well-characterised consecutive series of breast cancer (4,987 cases), from a single institution, with a long-term follow-up to assess the prognostic value of routine assessment of histologic grade in ILC. Histologic grade and other clinicopathological data were available in 517 pure ILC cases. A panel of biomarkers was also available for 215 cases. Results: The majority of ILC was of classical and mixed lobular variants (89%). Most ILC cases were moderately differentiated (grade 2) tumours (76%), while a small proportion of tumours were either grade 1 or 3 tumours (12% each). There were positive associations between histologic grade and other clinicopathological variables of poor prognosis such as larger size, positive lymph node, vascular invasion, oestrogen receptor and androgen receptor negativity and p53 positivity. Multivariate analyses showed that histologic grade is an independent predictor of shorter breast cancer specific survival and disease free interval. Conclusion: Histologic grade of ILC, as assessed by the Nottingham grading system, provides a strong predictor of outcome in patients with invasive lobular carcinoma of the breast and should be provided routinely in pathology reports.

Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377PubMed

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

Symmers WC (1998) Assessment of histological grade. systemic pathology. In: Elston CW, Ellis IO (eds) The Breast, vol. 13. Churchill Livingstone, Edinburgh, p 381

Pereira H, Pinder SE, Sibbering DM et al (1995) Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 27:219–226PubMedCrossRef

Sundquist M, Thorstenson S, Brudin L et al (1999) Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 53:1–8PubMedCrossRef

Dalton LW, Page DL, Dupont WD (1994) Histologic grading of breast carcinoma. A reproducibility study. Cancer 73:2765–2770PubMedCrossRef

Frierson HF Jr, Wolber RA, Berean KW et al (1995) Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195–198PubMed

Robbins P, Pinder S, de Klerk N et al (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26:873–879PubMedCrossRef

Elston CW, Ellis IO, Pinder SE (1999) Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 31:209–223PubMedCrossRef

10.

Balslev I, Axelsson CK, Zedeler K et al (1994) The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32:281–290PubMedCrossRef

11.

D’Eredita G, Giardina C, Martellotta M et al (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591–596PubMedCrossRef

12.

Okugawa H, Yamamoto D, Uemura Y et al (2005) Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution. Surg Today 35:907–911PubMedCrossRef

13.

Third Edition of the NHS Breast Screening Programme’s Guidelines for Pathology Reporting in Breast Cancer Screening and the 2nd edn., of The Royal College of Pathologists’ Minimum Dataset for Breast Cancer Histopathology. Pathology reporting of breast disease. Sheffield, January 2005. NHSBSP Pub. No 58

14.

European Commission (1996) In: de Wolf CJM, Perry NM (eds) European guidelines for quality assurance in mammography screening. Office for Official Publications of the European Communities, Luxembourg

15.

WHO classification of Tumours (2003) In: Tavassoli FA, Devilee P (eds) Pathology and genetics. Tumours of the breast and female genital organs. IARC press, Lyon

16.

Galea MH, Blamey RW, Elston CE et al (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219PubMedCrossRef

17.

Hanrahan EO, Valero V, Gonzalez-Angulo AM et al (2006) Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 24:2113–2122PubMedCrossRef

18.

Tavassoli F, Devilee P (2003) World health organization classification of tumours. In: Kleihues P, Sobin L (eds) Tumours of the breast and female genital organs. IARCPress

19.

Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978PubMed

20.

Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628–3636PubMedCrossRef

21.

Sastre-Garau X, Jouve M, Asselain B et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113–120PubMedCrossRef

22.

Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156PubMedCrossRef

23.

Martinez V, Azzopardi JG (1979) Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 3:467–488PubMedCrossRef

24.

Borst MJ, Ingold JA (1993) Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114:637–641; discussion 641–642PubMed

25.

Talman ML, Jensen MB, Rank F (2007) Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol 46:803–809PubMedCrossRef

26.

Sinn HP, Kellerhoff NM, Kellerhoff R et al (1997) Subtyping and prognostic assessment of invasive lobular breast carcinoma. Pathologe 18:37–44PubMedCrossRef

27.

Moreno-Elola A, Aguilar A, Roman JM et al (1999) Prognostic factors in invasive lobular carcinoma of the breast: a multivariate analysis. A multicentre study after seventeen years of follow-up. Ann Chir Gynaecol 88:252–258PubMed

28.

Bane AL, Tjan S, Parkes RK et al (2005) Invasive lobular carcinoma: to grade or not to grade. Mod Pathol 18:621–628PubMedCrossRef

29.

Sinha PS, Bendall S, Bates T (2000) Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers? Eur J Surg Oncol 26:733–737PubMedCrossRef

30.

Ellis IO, Galea M, Broughton N et al (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20:479–489PubMedCrossRef

31.

du Toit RS, Locker AP, Ellis IO et al (1989) Invasive lobular carcinomas of the breast—the prognosis of histopathological subtypes. Br J Cancer 60:605–609PubMed

32.

Pinder SE, Ellis IO, Galea M et al (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24:41–47PubMedCrossRef

33.

Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRef

34.

Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRef

35.

Rakha EA, Putti TC, Abd El-Rehim DM et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495–506PubMedCrossRef

36.

Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661–671PubMedCrossRef

37.

Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91:1532–1542PubMedCrossRef

38.

Schumacher M, Schmoor C, Sauerbrei W et al (1993) The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 25:235–245PubMedCrossRef

39.

Davis BW, Gelber RD, Goldhirsch A et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670PubMedCrossRef

40.

Page DL (1997) Prognostic indicators in breast cancer and who needs them. Anat Pathol 2:35–52PubMed

41.

Roberts MM, Alexander FE, Anderson TJ et al (1990) Edinburgh trial of screening for breast cancer: mortality at 7 years. Lancet 335:241–246PubMedCrossRef

42.

Ladekarl M, Sorensen FB (1993) Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast. Cancer 72:2602–2611PubMedCrossRef

43.

Mokbel K (2001) Grading of infiltrating lobular carcinoma. Eur J Surg Oncol 27:609–610PubMedCrossRef

Title: Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast
Authors: Emad A. Rakha
Maysa E. El-Sayed
Sindhu Menon
Andrew R. Green
Andrew H. S. Lee
Ian O. Ellis
Publication date: 01-09-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9768-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer

Medical cost-offsets from psychosocial care in breast cancer

The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study

Association of polymorphisms of angiogenesis genes with breast cancer

Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers

A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer